JP2017526706A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526706A5
JP2017526706A5 JP2017513199A JP2017513199A JP2017526706A5 JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5 JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049213 external-priority patent/WO2016040498A1/en
Publication of JP2017526706A publication Critical patent/JP2017526706A/ja
Publication of JP2017526706A5 publication Critical patent/JP2017526706A5/ja
Pending legal-status Critical Current

Links

JP2017513199A 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物 Pending JP2017526706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048759P 2014-09-10 2014-09-10
US62/048,759 2014-09-10
US201562146794P 2015-04-13 2015-04-13
US62/146,794 2015-04-13
PCT/US2015/049213 WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017526706A JP2017526706A (ja) 2017-09-14
JP2017526706A5 true JP2017526706A5 (cg-RX-API-DMAC7.html) 2018-10-18

Family

ID=55459522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513199A Pending JP2017526706A (ja) 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物

Country Status (6)

Country Link
US (2) US10428029B2 (cg-RX-API-DMAC7.html)
EP (1) EP3193603A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017526706A (cg-RX-API-DMAC7.html)
AU (1) AU2015315167A1 (cg-RX-API-DMAC7.html)
CA (1) CA2960274A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016040498A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3193605A4 (en) 2014-09-10 2018-04-18 Epizyme, Inc. Substituted piperidine compounds
US10106510B2 (en) 2014-09-10 2018-10-23 Epizyme, Inc. Substituted isoxazoles for treating cancer
AU2015315180A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamides as irreversible SMYD inhibitors
WO2016040505A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
WO2016204006A1 (ja) 2015-06-17 2016-12-22 住友化学株式会社 有害節足動物防除剤
CU20210018A7 (es) * 2018-09-21 2021-10-12 Novartis Ag Compuestos de isoxazol-3-carboxamida
CN109879868B (zh) * 2019-03-07 2022-04-22 南通大学 含2-芳基噁唑结构的吡唑酰胺类化合物的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
DE19930075A1 (de) * 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
GB0017518D0 (en) * 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク エンド カムパニー インコーポレーテッド N−置換非アリール複素環アミジル系nmda/nr2b拮抗薬
US20040204341A1 (en) 2001-06-12 2004-10-14 Christopher Allen Nr2b receptor antagonists for the treatment or prevention of migraines
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1643960A2 (en) * 2003-07-02 2006-04-12 Merck & Co., Inc. Arylsulfonamide derivatives
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
AU2005317870A1 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
MX2009011816A (es) * 2007-05-03 2009-11-19 Pfizer Ltd Derivados de piridina.
US20090062286A1 (en) 2007-05-04 2009-03-05 Kenneth William Foreman Crystal Structure of SMYD3 Protein
CN102725296B (zh) * 2010-01-29 2015-04-01 韩美科学株式会社 对蛋白激酶有抑制活性的噻吩并[3,2-d]嘧啶衍生物
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
ES2869328T3 (es) * 2012-12-18 2021-10-25 Alcyone Lifesciences Inc Dispositivos y métodos para reducir o evitar un reflujo en un sistema de administración
BR112015023294A2 (pt) * 2013-03-15 2017-07-18 Shifa Biomedical Corp método para tratamento ou prevenção de uma doença
WO2016040508A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
US10106510B2 (en) 2014-09-10 2018-10-23 Epizyme, Inc. Substituted isoxazoles for treating cancer
EP3193605A4 (en) 2014-09-10 2018-04-18 Epizyme, Inc. Substituted piperidine compounds
AU2015315180A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamides as irreversible SMYD inhibitors
CA2960273A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine compounds
WO2016040505A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors

Similar Documents

Publication Publication Date Title
JP2017526706A5 (cg-RX-API-DMAC7.html)
JP2017528464A5 (cg-RX-API-DMAC7.html)
JP2016514695A5 (cg-RX-API-DMAC7.html)
JP2017527577A5 (cg-RX-API-DMAC7.html)
JP2017528460A5 (cg-RX-API-DMAC7.html)
JP2017538659A5 (cg-RX-API-DMAC7.html)
JP2019514950A5 (cg-RX-API-DMAC7.html)
MA40581A (fr) Dérivés pyridone utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
JP2017527576A5 (cg-RX-API-DMAC7.html)
RU2014112345A (ru) Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, фармацевтическая композиция, содержащая это соединение, и его применение
CN103402519B (zh) 肿瘤治疗剂
JP2017510641A5 (cg-RX-API-DMAC7.html)
CY1118730T1 (el) Παραγωγα πυριδινης ως αναστολεις της αναδιαταχθεισας κατα την διαρκεια διαλοιμωξης (ret) κινασης
CA3094449A1 (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
IL272697B2 (en) A polymorphic form of TG02
IL312936A (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo-[1,2-A] pyrido [3,4-E] pyrimidine-5(1H)-one, analogs and salts thereof, and methods of use for therapy
JP2016521280A5 (cg-RX-API-DMAC7.html)
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
JP2017528461A5 (cg-RX-API-DMAC7.html)
HRP20211877T1 (hr) Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
JPWO2021188948A5 (cg-RX-API-DMAC7.html)
RU2017124371A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина
JP2016106092A (ja) 組合せ
JP2020506884A5 (cg-RX-API-DMAC7.html)
CA2994456A1 (en) Benzodiazepines as bromodomain inhibitors